Search

Contexte : La surveillance reguliere du cancer est essentielle pour comprendre ou des progres sont realises et ou il faut en faire plus. Nous avons cherche a donner un apercu du fardeau attendu du cancer au Canada, en 2022. Methodes : Nous avons obtenu les nouvelles donnees sur l'incidence du cancer a partir du Systeme national de declaration des cas de cancer (1984-1991) et du Registre canadien du cancer (1992-2018). Les donnees sur la mortalite (1984-2019) sont extraites de la Base canadienne de donnees sur les deces de la Statistique de l'etat civil. Nous avons projete les nombres et les taux d'incidence du cancer et de mortalite jusqu'en 2022 pour 22 types de cancer, par sexe et par province ou territoire. Les taux ont ete normalises selon l'age de la population type canadienne de 2011. Resultats : On estime a 233900 le nombre de nouveaux cas de cancer et a 85 100 le nombre de deces des suites du cancer au Canada en 2022. Nous nous attendons a ce que les cancers les plus frequemment diagnostiques soient le cancer du poumon en general (30 000), le cancer du sein chez les femmes (28 600) et le cancer de la prostate chez les hommes (24 600). De plus, le cancer du poumon devrait etre la principale cause de deces lie au cancer, representant 24,3 % de l'ensemble des deces par cancer, suivi des cancers colorectal (11,0 %o), du pancreas (6,7 %o) et du sein (6,5 %o). On s'attend generalement a ce que les taux d'incidence et de mortalite soient plus eleves dans les provinces de l'est du Canada que dans celles de l'ouest. Interpretation : Bien que les taux globaux de cancer soient en baisse, le nombre de cas et de deces continue de grimper, en raison de la croissance demographique et du vieillissement demographique. Le fardeau eleve projete du cancer du poumon indique qu'il est necessaire de renforcer la lutte contre le tabagisme et d'ameliorer la detection precoce et le traitement. Les progres realises en matiere de depistage et de traitement du cancer du sein et du cancer colorectal expliquent probablement la diminution continue de leur fardeau. Les progres limites en matiere de detection precoce et de nouveaux traitements du cancer du pancreas expliquent pourquoi on s'attend a ce qu'il soit la troisieme cause de deces par cancer au Canada., Les consequences du cancer sur la population et les systemes de soins de sante canadiens sont considerables. Le cancer est la principale cause de deces au Canada (1,2) et des [...]

Background: Regular cancer surveillance is crucial for understanding where progress is being made and where more must be done. We sought to provide an overview of the expected burden of cancer in Canada in 2022. Methods: We obtained data on new cancer incidence from the National Cancer Incidence Reporting System (1984-1991) and Canadian Cancer Registry (1992-2018). Mortality data (1984-2019) were obtained from the Canadian Vital Statistics--Death Database. We projected cancer incidence and mortality counts and rates to 2022 for 22 cancer types by sex and province or territory. Rates were age standardized to the 2011 Canadian standard population. Results: An estimated 233900 new cancer cases and 85100 cancer deaths are expected in Canada in 2022. We expect the most commonly diagnosed cancers to be lung overall (30000), breast in females (28600) and prostate in males (24600). We also expect lung cancer to be the leading cause of cancer death, accounting for 24.3% of all cancer deaths, followed by colorectal (11.0%), pancreatic (6.7%) and breast cancers (6.5%). Incidence and mortality rates are generally expected to be higher in the eastern provinces of Canada than the western provinces. Interpretation: Although overall cancer rates are declining, the number of cases and deaths continues to climb, owing to population growth and the aging population. The projected high burden of lung cancer indicates a need for increased tobacco control and improvements in early detection and treatment. Success in breast and colorectal cancer screening and treatment likely account for the continued decline in their burden. The limited progress in early detection and new treatments for pancreatic cancer explains why it is expected to be the third leading cause of cancer death in Canada., The impact of cancer on the Canadian population and health care systems is substantial. Cancer is the leading cause of death in Canada (1,2) and previous estimates have shown that [...]

Edge vision devices face real 3-D scenes with lighting fluctuations. They require a vision chip capable of acquiring 2-D/3-D vision with a high dynamic range and performing real-time intelligent in situ processing, while maintaining low end-to-end latency. Aimed at this versatile edge vision, this article presents a bio-inspired full-spiking vision chip that consists of a single-photon-avalanche-diode (SPAD) image sensor and a spiking vision processor monolithically. To decrease latency while realizing versatile functions, we build a bio-inspired full spiking vision on chip by directly coupling spike-like SPAD imaging with a neuroinspired spike-computing paradigm. By modeling this spiking visual flow, we theoretically demonstrate direct coupling and derive a spike preprocessing method for dim-vision enhancement. The SPAD image sensor equipped with a configurable exposure gating scheme can realize three modes: 2-D, 3-D depth, and dim-vision imaging. The spiking vision processor contains a parallel processing element (PE) array and can be reconfigured as a preprocessor or a spiking neural network (SNN) processor. A prototype chip integrated with a $128 \,\, \times \,\, 128$ SPAD image sensor with a reconfigurable spiking vision processor (256 PEs) was implemented in a 0.18- $\mu \text{m}$ CMOS technology. The chip experimentally demonstrates three imaging modes, 99.30% classification accuracy on the MNIST dataset with 2-D vision, only 3.9% accuracy loss under 0.02 lux with dim-vision, 1.68 cm obstacle detection error with 3-D depth vision, and a 3.58 $\mu \text{s}$ latency for light adaptation. The chip realizes a 100 dB dynamic range, 100 000 spiking maps per second (SMps), and 81.92 GSOPS at an 80-MHz clock.